David A. Siegel C4 Therapeutics, Inc. Call Options Transaction History
Two Sigma Advisers, LP
- $42.5 Billion
- Q1 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding CCCC
# of Institutions
111Shares Held
49.4MCall Options Held
455KPut Options Held
429K-
State Street Corp Boston, MA7.15MShares$33 Million0.0% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT4.33MShares$20 Million0.19% of portfolio
-
Commodore Capital LP New York, NY3.41MShares$15.8 Million2.41% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.92MShares$13.5 Million0.0% of portfolio
-
Soleus Capital Management, L.P. Greenwich, CT2.46MShares$11.4 Million1.64% of portfolio
About C4 Therapeutics, Inc.
- Ticker CCCC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 48,913,800
- Market Cap $226M
- Description
- C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting ...